Life Stem Genetics is Pleased to Announce That It Has Completed the First $500,000 Private Placement of the Recently …

LOS ANGELES--(BUSINESS WIRE)--

Life Stem Genetics (LIFS) is pleased to announce that it has completed and received the first $500,000 of the recently announced $1mm Private Placement. Our company is very happy to receive the first half of our recent private placement and hopes to close the additional $500,000 in the coming weeks.

The money will be used to attract additional affiliate offices country wide and to invest in various areas of research and development in moving our company's plans forward.

About Life Stem Genetics

Life Stem Genetics (LSG) is a progressive health care company that focuses on healing with a patients own Stem Cells. Stem Cells for years have been known to heal a variety of ailments successfully and now it is being offered as an efficient and painless way to treat many different illnesses ranging from orthopedic injuries, neurological disorders such as Parkinsons and Alzheimers, Cancer, Plastic Surgery, Age Management, Arthritis, Diabetes, Cardiology, COPD, MS, Urology, and many more. Stem Cell Therapy and LSGs proprietary techniques have experienced some of the best results in the industry, helping to repair or re-program damaged or diseased tissues and organs.

LSGs stem cell specialist has performed thousands of stem cell treatments, including the top names in PGA golf, NFL football, NBA basketball, and Major League Baseball. LSG will offer their proprietary treatments through a series of affiliate doctors, and medical clinics, with 60 affiliated clinics so far.

LSGs mission is to create a solid comprehensive approach to the treatment and maintenance of diseases and to break free from the medical insurance world by tapping into an affordable private-pay sector delivering exceptional healthcare free from the medical insurance maze.

http://www.lifestemgenetics.com/

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may, could, estimates, "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and the Company's future performance, operations, and products. Such statements involve known and unknown risks, uncertainties and other factors that could cause the Company's actual results to differ materially from the results expressed or implied by such statements. Such risks and uncertainties include, without limitation, market acceptance of the Company's stem cell therapy treatment program; the Company's compliance with applicable statutes and regulations: the Company's reliance on third-party contractors to provide suitable treatment facilities; the Company's ability to expand its network of participating clinics and doctors; the Company's ability to develop an effective marketing strategy; the Company's ability to control and reduce advertising and marketing costs; the Company's ability to develop and increase awareness of its brand; the Company's ability to protect its trademarks; and the success of the Company's marketing focus to patients, doctors and clinics. For a discussion of these and other risks and uncertainties see "Risk Factors" and Description of Business in the Company's public filings with the SEC. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

Go here to read the rest:
Life Stem Genetics is Pleased to Announce That It Has Completed the First $500,000 Private Placement of the Recently ...